神经科学
We’re delivering science that takes us closer to meaningful change for people with neurological and psychiatric disorders.\r\n"}}" id="text-780228e2b3" class="cmp-text">
我们提供科学能让我们更有意义的改变的神经和精神障碍患者。
为什么我们专注于保护人格
In the field of neuroscience, with many tough-to-treat disorders and high unmet need, our scientists are relentless in their pursuit of raising the standards of care. But the brain is complex, and new challenges require new ways of thinking across all stages of drug discovery and development.
\r\n
\r\nThat’s why we are continuously exploring innovative, disease-modifying approaches to address some of the most prevalent and serious disorders, from Parkinson’s and Alzheimer’s to migraine, schizophrenia and stroke.\r\n"}}" id="text-2db3203aff" class="cmp-text">
\r\n
\r\nThat’s why we are continuously exploring innovative, disease-modifying approaches to address some of the most prevalent and serious disorders, from Parkinson’s and Alzheimer’s to migraine, schizophrenia and stroke.\r\n"}}" id="text-2db3203aff" class="cmp-text">
在神经科学领域,许多tough-to-treat障碍和高未满足的需求,我们的科学家不懈的追求,提高治疗水平。但是大脑是复杂的,和新的挑战需要新的思考方式在所有阶段的药物发现和开发。狗万正网地址
这就是为什么我们不断探索创新,疾病修饰的方法来解决一些最普遍和严重的障碍,偏头痛帕金森症和阿尔茨海默氏症、精神分裂症和中风。
研究兴趣
We work across all stages of development in search of novel therapeutics and drug-device combinations that have the potential to treat chronic disabling neurological and psychiatric conditions. Our research interests include:\r\n
New disease modification approaches
\r\nInvestigating mechanisms supported by genetic, molecular and physiological discoveries, with an emphasis on pathological proteins, mitochondrial/lysosomal function, proteostasis, neuroinflammation, neuroprotection, and neurorehabilitation, with an emphasis on preventing the spread and mediating the clearance of toxic intracellular protein aggregates.
\r\n
\r\nManaging disease symptoms
\r\nAdvancing approaches that ameliorate the cognitive and behavioral deficits in Alzheimer's, Parkinson's disease and neuropsychiatric conditions.
\r\n
\r\nGenetic, molecular and physiological insights
\r\nInvestigating mechanisms supported by genetic, molecular and physiological discoveries, with an emphasis on pathological proteins, mitochondrial/lysosomal function, proteostasis, neuroinflammation, neuroprotection, and neurorehabilitation.
我们工作在所有的发展阶段的新疗法和drug-device组狗万正网地址合有可能治疗慢性禁用神经和精神疾病。我们的研究兴趣包括:
新的疾病的修改方法
调查机制由遗传、分子和生理发现,重点是病态的蛋白质,线粒体/溶酶体功能,proteostasis,神经炎症,神经保护,neurorehabilitation,重点是防止扩散和调停毒性细胞内蛋白质总量的间隙。
管理疾病症状
推进方法改善阿尔茨海默氏症的认知和行为的赤字,帕金森病和神经精神条件。
遗传、分子和生理的见解
调查机制由遗传、分子和生理发现,重点是病态的蛋白质,线粒体/溶酶体功能,proteostasis,神经炎症,神经保护,neurorehabilitation。
神经科学和精神领域
The burden of neurological and psychiatric disorders can feel insurmountable. But that feeling drives us to take on some of the biggest challenges and unearth potential solutions that consider the whole patient.\r\n"}}" id="text-f04594454b" class="cmp-text">
神经和精神疾病的负担可以感觉到不可逾越的。但这种感觉驱使我们采取一些最大的挑战和发掘潜在的解决方案,考虑整个病人。
外部链接
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.\r\n
Copyright © 2023 AbbVie Inc. North Chicago, Illinois, U.S.A.
\r\n"}}" id="text-f8847d5421" class="cmp-text">除非另有规定,所有产品名称出现在本网站商标或许可AbbVie Inc .旗下的子公司或分支机构。没有使用任何AbbVie商标,商号,或贸易服装在这个网站可能没有AbbVie Inc .的事先书面授权,除了确定公司的产品或服务。
版权©2023 AbbVie Inc .北芝加哥,伊利诺斯州,美国
